Crohn's disease

Crohn's disease
Denis Desaulniers et Bernard Têtu · CC BY-SA 4.0 · source
Name	Crohn's disease
Specialty	Gastroenterology

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract characterized by transmural inflammation and skip lesions affecting any segment from mouth to anus. It causes recurring abdominal pain, diarrhea, weight loss and systemic manifestations that may require long-term management by multidisciplinary teams. Presentation, course and response to therapy vary widely across populations and health systems.

Signs and symptoms

Typical features include crampy abdominal pain, chronic diarrhea and weight loss, often accompanied by fever, fatigue and anorexia. Extraintestinal manifestations occur in the joints, skin, eyes and hepatobiliary system and may include peripheral arthritis, erythema nodosum and uveitis. Complications such as intestinal obstruction, fistulae and perianal disease produce symptoms like obstructive cramps, fecal urgency and drainage; severe cases lead to malnutrition and growth failure in pediatric patients. Systemic markers may be reflected in laboratory tests performed in hospitals like Mayo Clinic, Cleveland Clinic and tertiary centers such as Johns Hopkins Hospital and Massachusetts General Hospital.

Causes and pathophysiology

Etiology is multifactorial, involving genetic susceptibility, environmental triggers and dysregulated mucosal immunity. Genome-wide association studies led by consortia including the Wellcome Trust and teams at Harvard Medical School have identified multiple susceptibility loci affecting innate and adaptive immunity. Microbial factors and alterations in the intestinal microbiome have been studied by investigators at institutions like Broad Institute and Sanger Institute, implicating shifts in bacterial communities. Immunological pathways include Th1 and Th17 responses modulated by cytokines such as tumor necrosis factor alpha, interleukin-12 and interleukin-23, targets investigated by pharmaceutical companies like AbbVie and Johnson & Johnson. Environmental risk modifiers include smoking, diet changes in urbanized regions and prior use of antibiotics studied by public health units such as Centers for Disease Control and Prevention and the World Health Organization.

Diagnosis

Diagnosis combines clinical assessment, endoscopic evaluation, histopathology and imaging. Ileocolonoscopy with biopsies at centers such as Mayo Clinic and Guy's and St Thomas' NHS Foundation Trust demonstrates segmental ulceration and granulomas in some patients. Cross-sectional imaging including magnetic resonance enterography and computed tomography enterography, performed at radiology departments like those at University College London Hospitals and Karolinska University Hospital, assesses transmural disease, strictures and fistulae. Laboratory tests including inflammatory markers and fecal calprotectin, and serologic panels reported by diagnostic labs such as Quest Diagnostics and LabCorp, support clinical probability. Multidisciplinary guideline panels from bodies including the European Crohn's and Colitis Organisation and the American Gastroenterological Association provide diagnostic criteria and algorithms.

Treatment

Therapeutic strategies aim to induce and maintain remission using medications, endoscopic intervention and surgery. Medical therapy ranges from aminosalicylates and corticosteroids to immunomodulators like azathioprine and biologic agents such as anti-TNF therapies (infliximab, adalimumab) developed by companies including Merck and Pfizer and newer agents targeting interleukin pathways. Nutritional therapy and exclusive enteral nutrition are used particularly in pediatric protocols at centers like Great Ormond Street Hospital and Birmingham Children's Hospital. Endoscopic balloon dilation and resection techniques are provided by gastrointestinal units at institutions like Cleveland Clinic and Mayo Clinic, while surgical options including ileocolic resection and stricturoplasty are performed by colorectal surgeons at hospitals such as Mount Sinai Hospital and Royal Marsden Hospital. Management increasingly incorporates patient advocacy organizations including Crohn's & Colitis Foundation and research funding from agencies like the National Institutes of Health.

Complications and prognosis

Complications include intestinal obstruction, fistulas, abscesses, colorectal dysplasia and extraintestinal manifestations in the skin, eyes and joints; long-term risk of colorectal cancer is managed with surveillance colonoscopy programs modeled by institutions like National Cancer Institute and Royal College of Physicians. Prognosis depends on disease location, severity, response to therapy and access to specialty care; cohorts followed at academic centers such as Stanford Health Care and Vanderbilt University Medical Center inform prognostic models. Quality of life and disability burden are addressed by multidisciplinary rehabilitation programs and social services in healthcare systems like the National Health Service and private insurers such as UnitedHealth Group.

Epidemiology

Incidence and prevalence have increased in many regions during the 20th and 21st centuries, especially in North America and Western Europe, with rising rates reported from centers in Canada, United States, United Kingdom and Scandinavia. Rising incidence has been observed in newly industrialized countries in Asia, Africa and South America, with surveillance initiatives by World Health Organization and regional public health agencies documenting demographic shifts. Disease onset peaks in adolescence and early adulthood, with pediatric cohorts described by academic programs at Children's Hospital of Philadelphia and Boston Children's Hospital contributing epidemiologic data.

History and society

Descriptions of chronic enteritis date to early clinical literature, with modern delineation by clinicians in the 20th century leading to eponymous recognition and differentiation from ulcerative colitis at centers like Mount Sinai Hospital and universities including Columbia University. Patient advocacy and fundraising by organizations such as Crohn's & Colitis Foundation and research consortia including the European Crohn's and Colitis Organisation have shaped care standards, public awareness campaigns and research agendas. Health policy, insurance coverage debates and workplace accommodations involve stakeholders including U.S. Food and Drug Administration, national health services and patient rights groups; media coverage and celebrity advocacy have also influenced public perception and funding priorities.

Category:Gastroenterology